$1.67
+0.01 (+0.60%)
Open$1.65
Previous Close$1.66
Day High$1.70
Day Low$1.62
52W High$14.85
52W Low$0.97
Volume—
Avg Volume56.2K
Market Cap10.94M
P/E Ratio—
EPS$-4.05
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+376.0% upside
Current
$1.67
$1.67
Target
$7.95
$7.95
$5.82
$7.95 avg
$9.13
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 913.8K | 821.5K | 988.8K |
| Net Income | -134,164 | -149,522 | -162,197 |
| Profit Margin | -14.7% | -18.2% | -16.4% |
| EBITDA | -201,888 | -178,889 | -216,043 |
| Free Cash Flow | -124,461 | -98,758 | -111,181 |
| Rev Growth | +16.4% | +11.0% | +21.1% |
| Debt/Equity | 1.08 | 0.86 | 0.85 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |